Læknablaðið - 15.12.2009, Qupperneq 17

FRÆÐIGREINAR
RANNSÓKN
8. Romano PS, Mark DH. Patient and hospital characteristics
related to in-hospital mortality after lung cancer resection.
Chest 1992; 101:1332-7.
9. Silvestri GA, Handy J, Lackland D, Corley E, Reed CE.
Specialists achieve better outcomes than generalists for iung
cancer surgery. Chest 1998; 114: 675-80.
10. Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and
mortality after neoadjuvant therapy for lung cancer: The
risks of right pneumonectomy. Ann Thorac Surg 2001; 72:
1149-54.
11. Mansour Z, Kochetkova EA, Ducrocq X, et al. Induction
chemotherapy does not increase the operative risk of
pneumonectomy! Eur J Cardiothorac Surg 2007; 31:181-5.
12. Doddoli C, Barlesi F, Trousse D, et al. One hundred
consecutive pneumonectomies after induction therapy for
non-small cell lung cancer: An uncertain balance between
risks and benefits. J Thorac Cardiovasc Surg 2005; 130: 416-
25.
13. Myrdal G, Gustafsson G, Lambe M, Horte LG, Stahle E.
Outcome after iung cancer surgery. Factors predichng early
mortality and major morbidity. Eur J Cardiothorac Surg 2001;
20: 694-9.
14. Patel RL, Townsend ER, Fountain SW. Elective
pneumonectomy: factors associated with morbidity and
operative mortality. Ann Thorac Surg 1992; 54: 84-8.
15. Ludwig C, Stoelben E, Oischewski M, Hasse J. Comparison
of morbidity, 30-day mortality, and long-term survival^fter
pneumonectomy and sleeve lobectomy for non-small celi
lung carcinoma. Ann Thorac Surg 2005; 79: 968-73.
16. Alexiou C, Beggs D, Rogers ML, Beggs L, Asopa S, Salama FD.
Pneumonectomy for non-Small cell lung cancer: predictors of
operative mortality and survival. Eur J Cardiothorac Surg
2001; 20: 476-80.
17. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW.
Treatment of non-small cell lung cancer-stage IIIA - ACCP
evidence-based clinical practice guidelines (2nd edition).
Chest 2007; 132: 243S-65S.
18. Park BJ, Flores R, Downey RJ, Bains MS, Rusch VW.
Management of major hemorrhage during mediastinoscopy.
J Thorac Cardiovasc Surg 2003; 126: 726-31.
19. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol
Clin North Am 2007; 45: 21-43.
20. Whitson BA, Groth SS, Maddaus MA. Surgical assessment
and Intraoperative management of mediastinal lymph nodes
in non-small cell lung cancer. Ann Thorac Surg 2007; 84:1059-
65.
21. Manser R, Wright G, Hart D, Byrnes G, Campbell DA.
Surgery for early stage non-small cell lung cancer. Cochrane
Database Syst Rev 2005: CD004699.
22. Rosell R, Gomezcodina J, Camps C, et al. A randomized trial
comparing preoperative chemotherapy plus surgery with
surgery alone in patients with non-small-cell lung cancer. N
Engl J Med 1994; 330:153-8.
23. Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative
chemotherapy followed by surgery compared with primary
surgery in resectable stage I (except T1N0), II, and Illa non-
small-cell lung cancer. J Clin Oncol 2002; 20: 247-53.
24. Pisters KMW, Le Chevalier T. Adjuvant chemotherapy in
completely resected non-small-cell lung cancer. J Clin Oncol
2005; 23: 3270-8.
25. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus
cisplatin vs. observation in resected non-small-cell lung
cancer. N Engl J Med 2005; 352: 2589-97.
26. Fowler WC, Langer CJ, Curran WJ, Keller SM. Postoperative
complications after combined neoadjuvant treatment of lung
cancer.Ann Thorac Surg 1993; 55: 986-9.
27. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine
plus cisplatin versus observation in patients with completely
resected stage IB-IIIA non-small-cell lung cancer (Adjuvant
Navelbine Intemational Trialist Association [ANITA]): a
randomised controlled trial. Lancet Oncol 2006; 7: 719-27.
28. Ginsberg RJ, Hill LD, Eagan RT, et al. Modem thirty-day
operative mortality for surgical resections in lung cancer. J
Thorac Cardiovasc Surg 1983; 86: 654-8.
29. Kadri MA, Dussek JE. Survival and prognosis following
resection of primary non small cell bronchogenic carcinoma.
Eur J Cardiothorac Surg 1991; 5:132-6.
30. Ramnath N, Demmy TL, Antun A, et al. Pneumonectomy
for bronchogenic carcinoma: analysis of factors predicting
survival. Ann Thorac Surg 2007; 83:1831-6.
Results of pneumonectomy for non-small cell lungcancer in lceland
Objective: Study the indications, complications and
surgical outcome of pneumonectomy for non small cell
lung cancer (NSCLC) in lceland
Material and methods: A retrospective study of all
pneumonectomies performed for NSCLC in lceland from
1988 to 2007. Information was obtained from medical
records and data on operative indications, postoperative
TNM stage, complictions, survival and survival predictors
was analysed.
Results: 77 patients (64% males) with mean age of
62.3 yrs. were operated on, 44% on the right side.
Mediastinoscopy was performed in 31 % of cases. Most
patients were stage I or II (58%), but 17 and 21% were
stage III A and IIIB, respectively. Mean operation time
was 161 min., bleeding 1.1 Land hospital stay 11 days.
Atrial fibrillation (21%), pneumonia (6.5%), empyema
(5.5%) and respiratory failure (5%) were the most common
complications. Three (3.9%) patients died within 30 days
from surgery. Five year survival was 20.7%. Age, history
of COPD, adenocarcinoma histology and advanced TNM
stage were independent predictors of poor survival.
Conclusions: Pneumonectomies for NSCLC in lceland
have a low rate of complications and operative mortality.
However, long term survival is lower than expected, and
many patients (27%) were in advanced stages. This is
most likely due to inadequate preoperative staging.
Thorsteinsson H, Alfredsson H, Isaksson HJ, Jonsson S, Gudbjartsson T.
Results of pneumonectomy for non-small cell lungcancer in lceland. Icel Med J 2009; 95:823-9
Key word: Lung cancer, pneumonectomy, results, complications, survival, predictors ofsurvival, multivariate analysis.
Correspondence: Tómas Guðbjartsson, tomasgud@landspitali.is
>-
CC
<
2
S
D
W
X
tn
_i
o
2
UJ
Barst: 7. júlí 2009, - samþykkt til birtingar: 21. október 2009
LÆKNAblaðið 2009/95 829